Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
- PMID: 31395036
- PMCID: PMC6686531
- DOI: 10.1186/s12885-019-6000-y
Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
Abstract
Background: NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial response to four therapy cycles and later progression.
Methods: Thirty five patients (pat.) (25 male, 10 female, 63 ± 9 years) with progressive, metastasized NET (23 small intestinal, 5 lung, 4 CUP, 1 rectal, 1 gastric and 1 paraganglioma) were included. All patients previously received 4 PRRT cycles with 177Lu-DOTATATE and showed initial response. SPECT based dosimetry was applied to determine kidney and tumor doses. Therapy response was evaluated using 68Ga-DOTATATE PET/CT (with high dose CT), CT alone or MRI (RECIST 1.1), toxicity was defined using CTCAE 5.0 criteria. 99mTc99-MAG3 scintigraphy was used to assess potential renal tubular damage. Progression free survival (PFS) and Overall survival (OS) analysis was performed with the Kaplan-Meier-method.
Results: The median PFS after initial PRRT was 33 months (95% CI: 30-36). The mean cumulative dose for including salvage PRRT was 44 GBq (range 33.5-47). One pat. (2.9%) showed grade 3 hematotoxicity. Kidney dosimetry revealed a mean cumulative kidney dose after a median of 6 PRRT cycles of 23.8 Gy. No grade 3 / 4 nephrotoxicity or relevant decrease in renal function was observed. Follow-up imaging was available in 32 patients after salvage therapy. Best response according to RECIST 1.1. was PR in one patient (3.1%), SD in 26 patients (81.3%) and PD in 5 patients (15.6%). PFS after salvage therapy was 6 months (95% CI: 0-16; 8 patients censored). Mean OS after initial PRRT was 105 months (95% CI: 92-119) and 51 months (95% CI: 41-61) after start of salvage therapy. Median OS was not reached within a follow-up of 71 months after initial PRRT and 25 months after start of salvage PRRT, respectively.
Conclusions: Salvage therapy with 177Lu-DOTATATE is safe and effective even in patients with extensive previous multimodal therapies during disease progression and represents a feasible and valuable therapy option for progressive NET.
Keywords: Dosimetry; NET; PRRT; SPECT; Salvage therapy; Survival.
Conflict of interest statement
HI is an advisory board member of Bayer, received research funding from Novartis and speaker honoraria from Bayer and Ipsen. CA has received research contracts from Ipsen, Novartis, and ITM Solucin, lecture honorarium from Ipsen, Novartis, and Falk Foundation, and advisory board honorarium from Novartis. CS has received research grants from Novartis, lecture honoraria from Ipsen and Novartis, and advisory board honoraria from Ipsen, Novartis, and Pfizer. All other authors declare no competing interests.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6686531/bin/12885_2019_6000_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6686531/bin/12885_2019_6000_Fig2_HTML.gif)
Similar articles
-
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?Front Endocrinol (Lausanne). 2022 Oct 31;13:941832. doi: 10.3389/fendo.2022.941832. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387893 Free PMC article. Review.
-
The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT.Br J Radiol. 2022 Sep 1;95(1137):20210896. doi: 10.1259/bjr.20210896. Epub 2022 Jul 21. Br J Radiol. 2022. PMID: 35816545 Free PMC article.
-
Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting.Br J Radiol. 2021 Jan 1;94(1117):20201041. doi: 10.1259/bjr.20201041. Epub 2020 Oct 29. Br J Radiol. 2021. PMID: 33095671 Free PMC article.
-
Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.Curr Radiopharm. 2019;12(2):126-134. doi: 10.2174/1874471012666190201164132. Curr Radiopharm. 2019. PMID: 30714538 Review.
-
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28. Eur J Nucl Med Mol Imaging. 2019. PMID: 30267116 Free PMC article.
Cited by
-
Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.J Gastrointest Cancer. 2024 May 23. doi: 10.1007/s12029-024-01065-z. Online ahead of print. J Gastrointest Cancer. 2024. PMID: 38780680
-
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Curr Oncol Rep. 2024 May;26(5):538-550. doi: 10.1007/s11912-024-01526-5. Epub 2024 Apr 6. Curr Oncol Rep. 2024. PMID: 38581469 Free PMC article. Review.
-
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.Front Endocrinol (Lausanne). 2023 Nov 20;14:1187870. doi: 10.3389/fendo.2023.1187870. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38053729 Free PMC article. Review.
-
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1136-1146. doi: 10.1007/s00259-023-06544-2. Epub 2023 Dec 2. Eur J Nucl Med Mol Imaging. 2024. PMID: 38040931
-
Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center.Cureus. 2023 Oct 23;15(10):e47506. doi: 10.7759/cureus.47506. eCollection 2023 Oct. Cureus. 2023. PMID: 38021538 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous